In the cancer research field, the preferred method for evaluating the proliferative activity of cancer cells in vivo is to measure DNA synthesis rates. The cellular proliferation rate is one of the most important cancer characteristics, and represents the gold standard of pathological diagnosis. Positron emission tomography Core tip: There is a continuous demand to measure in situ DNA synthesis rates in living human cancer. The thymidine derivative 4′-[methyl-
INTRODUCTION

Rationale for DNA synthesis imaging
The basic principle of DNA synthesis measurement using positron emission tomography (PET) and the rationale for tracer development for DNA synthesis imaging were extensively reviewed by Bading et al [1] , and Toyohara et al [2] , respectively. Briefly, thymidine is the only nucleoside that is exclusively incorporated into DNA. Therefore, DNA incorporation using [methyl-3 H]-thymidine is used as the gold standard for a cell proliferation marker. The challenge in visualizing in vivo DNA synthesis with 11 C-thymidine has been pursued since 1972 [3] . Extensive developments in the 1990s and early 2000s realized the estimation of thymidine flux from blood to DNA in somatic and brain tumors [4] [5] [6] [7] . From these studies, it became clear that the routine use of 11 C-thymidine has several limitations, including issues related to the use of radiolabeled catabolites, the short half-life of 11 C, and relatively difficult synthesis. While 11 C-thymidine is effectively incorporated into DNA, it is also rapidly catabolized by thymidine phosphorylase, which complicates image analysis. Thymidine is a substrate for mitochondrial thymidine kinase 2 as well as cytosolic thymidine kinase 1, which leads to the absence of cell proliferation related uptake in tissues with high mitochondria content, such as the heart. Therefore, the ideal tracer for DNA synthesis imaging requires resistance to catabolism by thymidine phosphorylase, selective phosphorylation by thymidine kinase 1, and ready incorporation into DNA (Figure 1 ).
4′-[methyl-
11
C] thiothymidine
4′-[methyl-
11 C] thiothymidine ( 11 C-4DST) is a derivative of thymidine in which the 4′-oxygen is replaced with sulfur and the 5-methyl group is radiolabeled with 11 C by the C-C cross-coupling reaction ( Figure 2 ) [8, 9] . The first synthesis conditions reported involved using 5-tributylstannyl-4′-thio-2′-deoxyuridine (precursor)/tris (dibenzylideneacetone) dipalladium (0) [Pd2(dba)3]/tri(otryl) phosphine [P(o-CH3C6H4)3] (1.5:1:3.9 in molar ratio) at 130 ℃ for 5 min in N,N-dimethylformamide (DMF), which gave the desired products at only 30% decaycorrected yields based on [ 11 C]CH3I [9] . Subsequently, slight modifications of the conditions, using precursor/ Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (1.5:1:3.9:4:3.6) at 80 ℃, resulted in greatly improved decay-corrected yields (70%) based on [ 11 C]CH3I [10] . Other reported conditions using precursor/Pd2(dba)3/P(o-CH3C6H4)3/ CuCl/K2CO3 (25:1:32:2:5) at 80 ℃ also gave improved decay-corrected yields (42%-60%) using the two-pot method, and 65% by the one-pot method based on 11 C-CH3I [11, 12] . Preclinical evaluation indicated that the stability of 11 C-4DST within the body is higher than that of thymidine, and unlike 3′-deoxy-3′-[ , it is taken up into DNA as a substrate for DNA synthesis. Therefore, Toyohara et al [8, 9] postulated that 11 C-4DST might be used as a valid in vivo DNA synthesis marker.
11
C-4DST was developed at the National Institute of Radiological Sciences (NIRS; Chiba, Japan) and has been approved for clinical use by the committee for medical use of cyclotron-produced radiopharmaceuticals of NIRS, as well as the medical use of cyclotron-produced radiopharmaceuticals and ethics committees of Tokyo Metropolitan Institute of Gerontology (TMIG; Tokyo, Japan). The first-in-human study was performed at TMIG in March 2010.
C-4DST was also described as 11 C-S-dThd [8, 9] , however, the names have since been unified to 11 C-4DST with the commencement of its clinical use [10] .
INITIAL CLINICAL TRIAL
An initial clinical trial of 11 C-4DST, which was equivalent to a phase 1 trial, was performed according to guidelines approved in January 2008 by the institutional committee of TMIG for first-in-human use of novel radiopharmaceuticals. Briefly, five brain tumor patients volunteered to participate in a study of the side effects associated with administration of 11 C-4DST, which
were assessed by clinical symptoms, physical findings, and blood tests. Concurrently,
11
C-4DST dynamic PET measurements were performed to assess the efficacy with which the desired function (DNA synthesis) can be measured. In addition, radiation dosimetry was estimated through whole-body PET measurement in three healthy volunteers.
The results of the initial clinical trial revealed no adverse events accompanying administration of 11 C-4-DST, and the effective dose was calculated as 4.2 µSv/ MBq. Whole-body PET indicated 11 C-4DST accumulations in bone marrow and spleen, where DNA synthesis is active in the adult. These observations suggest that 11 C-4DST uptake reflects the dynamics of DNA synthesis activity ( Figure 3 ). In addition, physiological accumulation of radioactivity was observed in the liver, kidney, and salivary glands, which are components of the metabolic excretion pathway. The levels of 11 C-4DST accumulation in the mediastinum, cerebral parenchyma, lungs, cardiac muscles, and skeletal muscles were very low.
The distribution of 11 C-4DST within the human body was different from that in rodents, and a high level of 11 C-4DST accumulation was observed in the human liver. This may have been due to species differences in 11 C-4DST metabolism; the metabolism of C-4DST is a nucleoside derivative and therefore does not readily pass through the blood-brain barrier. Thus, accumulation of radioactivity in normal brain is low. However, the majority of brain tumor lesions could be imaged, and the accumulation of Figure 4A shows a case that was resistant to the anticancer agent temozolomide, while the Figure 4B shows a case that was responsive to temozolomide. As can be seen in this figure, 
KINETIC ANALYSIS
Time-activity curves (TACs) of 11 C-4DST accumulation in brain tumors indicated irreversible kinetics, suggesting that 11 C-4DST might be metabolically trapped. In addition, Patlak graph analysis showed a linear plot, which supports the above suggestion [8, 9] . The results of the preliminary kinetic analysis indicated that 11 C-4DST was irreversibly taken up into the DNA because 11 C-4DST fits the two-tissue three-compartment model, and k4 is negligibly small. The value of k3 (k4 = 0) obtained by the analysis showed a strong correlation with Ki (k4 = 0), which reflects the rate of 11 C-4DST incorporation flux (Pearson's r = 0.925, P = 0.001), and no correlation was observed with K1 (k4 = 0), which reflects intracellular transport. In addition, the standardized uptake value (SUV) showed the best correlation with Ki (Patlak) and also showed good correlations with Ki (k4 = 0) and k3 (k4 = 0) (Pearson's r = 0.942, P = 0.0005; r = 0.857, P = 0.0065, respectively). The above results suggest that images of DNA synthesis might be obtained through non-quantitative analysis using SUV images.
In addition, we performed a basic validation study of 11 C-4DST accumulation kinetics into the DNA. The time course of the DNA uptake ratio in proliferating tissues in rats was illustrated by a Michaelis-Mententype hyperbolic curve, and 50% of the radioactivity was taken into DNA at 5 and 8 min after administration in the duodenum and spleen, with maximum uptake ratios of 99% and 94%, respectively. The TACs of these tissues as a whole were almost identical to the TACs of DNA incorporated radioactivity (DNA fraction) and were different from the soluble non-DNA fraction (unchanged form + phosphorylated form) ( Figure 5 ). On the other hand, in the AH109A rat liver cancer transplantation model, significant variation in DNA uptake rates between sampling sites was due to heterogeneity in the tumor tissues, with some regions exhibiting 60% DNA uptake at 1 min after administration (where cell proliferation is active). The above results indicate that the process of DNA uptake is the rate-limiting step in 11 C-4DST accumulation.
Furthermore, Plotnik et al [13] 
Salvage pathway
Catabolism adenocarcinoma cell line A549 under exponentialgrowth conditions. 3 H-4DST behaved qualitatively similar to endogenous thymidine in terms of equilibrative nucleoside transporter dependent cellular transport, shapes of cellular uptake curves, and relative DNA incorporation levels. As 4DST closely mimics thymidine metabolism, 11 C-4DST should provide a robust measurement of DNA synthesis. However, overall 3 H-4DST metabolism was significantly lower than that of thymidine, which may reflect its lower affinity toward thymidine kinase 1. This slower metabolism might limit its usefulness because of the relatively short half-life of the 11 C label, especially in the case of slow-growing tumors like prostate cancer.
CLINICAL STUDY IN VARIOUS TUMOR TYPES
Although the presence of metabolites in blood was not desirable in terms of quantitative measurement, the results of the 11 C-4DST early clinical trials indicated that its usability exceeded the drawbacks. In addition, as 11 C-4DST showed high uptake in the excretory organs, such as the kidneys, liver, and urinary bladder. Moderate uptake was observed in the proliferative organs, such as bone marrow, spleen, and small intestine. The lowest uptake was observed in the non-proliferating tissues, such as muscle and lungs. This research was originally published in JNM [10] . 11 C-4DST: 4'-[methyl-11 C]-thiothymidine; SUV: Standardized uptake value.
Gd-MRI In the case of recurrent anaplastic oligodendroglioma (A), both 11 C-MET and 11 C-4DST showed high uptake in the gadolinium-enhanced region of the MRI. However, the distribution pattern of each tracer in the tumor region was not identical. The tumor in this patient showed progressive enlargement despite continuous treatment with the DNA alkylating agent temozolomide. In the case of recurrent anaplastic astrocytoma (B), the patient received one course of treatment with temozolomide 3 d before PET examinations, and it was found that the 11 C-4DST uptake was negligible in the gadoliniumenhanced region where high uptake of 11 C-MET was observed. The enhanced tumor mass in this patient remained unchanged over 6 mo after commencement of temozolomide treatment. These observations suggest that DNA synthesis in the tumor was suspended by temozolomide treatment. Reprinted from Nariai et al [14] , with the permission of Springer.
11 C-4DST: 4'-[methyl-11 C]-thiothymidine; 11 C-MET: 11 C-Methionine; Gd-MRI: Gadolinium-enhanced magnetic resonance image; PET: Positron emission tomography.
Toyohara J. Progress of 4DST PET research high usability of 11 C-4DST was expected from the basic data obtained in animal experiments [8, 9] , collaborative research was initiated with the National Center for Global Health and Medicine (NCGM; Tokyo, Japan) and Kagawa University (Kagawa, Japan). In this collaborative research, technology transfer of radiosynthesis was first performed and then an application was submitted to the ethics committee. The clinical trial was started at approximately the same time as the early clinical trial performed at TMIG. A study to fundamentally support the clinical data is also being conducted in collaboration with the University of Groningen Medical Center (UMCG; Groningen, The Netherlands) and the University of Washington (Seattle, WA).
BRAIN TUMORS
Initial clinical studies of 11 C-4DST in brain tumors were performed at TMIG [14] . Fourteen patients with brain tumors (11 malignant gliomas, 2 metastatic tumors, 1 craniopharyngioma, and 1 malignant lymphoma) were included and the uptake of 11 C-4DST and 11 C-MET into gadolinium-enhanced lesions on T1 weighted magnetic resonance image (MRI) was evaluated. In this study, Nariai et al [14] observed a unique characteristic of 11 C-4DST in one case. They observed a marked decrease of 11 C-4DST uptake into metastatic lung cancer 5 d after gamma knife therapy. Although ring form enhancement with cystic formation did not disappear completely, tumor growth ceased with this treatment and the patient has maintained favorable activity of daily living 1 year after treatment ( Figure 6 ). In another case, 11 C-4DST could differentiate oligodendroglioma from malignant transformation (Figure 7) . However, 11 C]-thiothymidine activity in the mouse duodenum. The data is presented as the SUVmean in the indicated fractions (n = 3-5). Rapid DNA separation was performed using the DNAzol reagent [30] . The increase in total tissue radioactivity paralleled that of DNA incorporated radioactivity. The soluble fraction (4DST itself, phosphorylated 4DST, and other metabolites) was low and stable at 30 min after tracer injection. The contribution of the DNA incorporation process overshadows both the phosphorylation and dephosphorylation rates at later phases of the PET scan. PET: Positron emission tomography; SUV: Standardized uptake value.
Gd-MRI
11
C-4DST
Pre Pre 24 d 5 d Figure 6 Early evaluation of the effectiveness of radiosurgery with 4'-[methyl-11 C]-thiothymidine positron emission tomography. A marked decrease in 11 C-4DST uptake into metastatic lung cancer was observed 5 d after gamma knife radiosurgery. Although ring form enhancement with cystic formation did not disappear completely, tumor growth was halted by this treatment and the patient has maintained favorable activity of daily living 1 year after treatment. These observations indicated that the effectiveness of gamma knife therapy was correctly monitored by 11 C-4DST only 5 d after treatment. Reprinted from Nariai et al [14] , with the permission of Springer. In a follow-up study, Tanaka et al [16] retrospectively evaluated 11 C-4DST uptake in 23 patients with newly diagnosed gliomas, and correlated the results with the Ki-67 index and tumor grade in comparison with 11 C-MET [16] .
11
C-4DST PET/CT showed a slightly lower detection rate for gliomas than 11 C-MET (87% vs 96%); however, the difference was not statistically significant. The tracer uptake for normal brain tissue of C-4DST and Ki-67 index for SUVmax (r = 0.46, P < 0.03), for T/N ratio (r = 0.43, P < 0.05), and for MTV (r = 0.68, P < 0.001) and between 11 C-MET MTV and Ki-67 index (r = 0.43, P < 0.04). Among them, the correlation coefficient between 11 C-4DST MTV and Ki-67 index was the highest. There was a significant difference in SUVmax of 11 C-4DST between grades II and IV (P < 0.03) and in MTV between grades II and IV (P < 0.0009) and grades III and IV (P < 0.02).
HEAD AND NECK CANCER
Ito et al [17] prospectively compared the diagnostic value F-FDG PET/CT in patients with head and neck squamous cell carcinoma (HNSCC) [17] . Thirty-eight patients with advanced HNSCC underwent 11 
C-4DST PET/CT and
18
F-FDG PET/CT before treatment. All patients were followed for 13.5 ± 7.5 mo to monitor recurrence. The total lesion glycolysis (TLG) for 18 F-FDG and total lesion proliferation (TLP) for 11 C-4DST were used as outcome measures of the combination of functional information and volumetric data to predict patient prognosis [18] [19] [20] [21] . Nine of the 38 patients with post-treatment recurrence were identified. Receiver operating characteristic curves for TLG3.0 (sensitivity: 89%; specificity: 72%) and TLP2.5 (sensitivity: 89%; specificity: 55%) showed the highest prognostic ability for recurrence. There was no significant correlation between the Ki-67 index and whether 
LUNG CANCER
At NCGM, the first study focused mainly on lung cancer cases [22] . The subjects were 18 primary lung cancer patients (19 lesions) who underwent segmental resection and lymph node dissection. 18 
F-FDG PET/CT and 11
C-4DST PET/CT were performed in these patients during the same period and SUVmax was measured at the lesioned region in each patient. The results and histopathological evaluation (e.g., Ki-67 index) were compared. The observed histological types included 16 adenocarcinomas (including bronchioloalveolar carcinoma), 2 squamous cell carcinomas, and 1 large cell carcinoma, and the average tumor size was 27.2 mm. The average levels of SUVmax in the primary tumors were 2.9 ± 1.0 and 6.2 ± 4.5 for 
Figure 7 4'-[methyl-
11 C]-thiothymidine uptake in oligodendroglioma. A patient was diagnosed with grade 2 astrocytoma during the initial operation. At the 1-year follow-up, an enhanced lesion appeared on MRI and 11 C-MET uptake increased around the initially resected lesion. These findings suggested that the malignant transformation of astrocytoma occurred. However, 11 C-4DST uptake into the tumor was not different from basal brain levels. The pathological diagnosis at the second operation was grade 2 oligodendrocytoma with a newly appearing oligodendroglioma component, but without malignant transformation. Reprinted from Nariai et al [14] , with the permission of Springer. C-4DST appears to be effective as a PET tracer in primary lung cancer indicating DNA synthetic activity (cell proliferation activity).
The diagnostic ability of 11 C-4DST for detecting regional lymph node metastasis of non-small cell lung cancer (NSCLC) was prospectively evaluated by the same group (NCGM) [23] . A total of 31 patients with NSCLC underwent 11 C-4DST PET/CT and 18 F-FDG PET/ CT. Patients were followed for up to 2 years to assess disease-free survival. A total of 123 nodal groups were defined for 27 patients, with proven malignancy in 17 nodal groups of 9 patients. The sensitivity on a per-node basis was significantly higher with 11 C-4DST than with 18 F-FDG (82.5% vs 29.4%, P < 0.002). In contrast, the specificity on a per-node basis was significantly lower with 11 C-4DST than with 18 F-FDG (71.7% vs 85.8%, P < 0.02). The disease-free survival rate with positive 11 C-4DST uptake in nodal lesions was 0.35, which was considerably lower than the rate of 0.83 with negative findings (P = 0.04). Interestingly, nodal staging by 11 C-4DST was the most influential prognostic factor (P = 0.05) among the factors tested. The high sensitivity of 11 C-4DST for nodal metastasis indicates that it may be efficient in detecting lymph node micrometastasis.
MULTIPLE MYELOMA
In whole-body imaging diagnosis of multiple myeloma (MM), it was demonstrated that myeloma has various characteristics that become prominent at different stages, including energy metabolism ( We hope to be able to accurately determine the periods where follow-up observation is sufficient and aggressive chemotherapy is necessary, to optimize treatment in such cases. Okasaki et al [24] prospectively evaluated the possibility of 11 C-MET and 11 C-4DST whole-body PET/CT when searching for bone marrow involvement in patients with MM, in comparison with those for 18 F-FDG PET/CT and aspiration cytology [24] . A total of 64 patients with MM or monoclonal gammopathy of undetermined significance (MUGS) underwent three whole-body PET/CT scans with , and uptake of both 11 C-4DST PET (E) and 18 F-FDG PET (F) identifies the lesion (arrow). However, 11 C-4DST images are clearer than 18 F-FDG images because of low physiologic 11 C-4DST in the mediastinum (blood pool). This research was originally published in JNM [22] . 
RENAL CELL CANCER
Minamimoto et al [25] evaluated the potential of 11 C-4DST PET/CT for imaging cellular proliferation in advanced clear cell renal cell cancer (RCC), compared with 18 F-FDG PET/CT [25] . Five patients with a single RCC lesion were examined. The typical tumor accumulation pattern of 18 F-FDG was diffuse or with a thick uptake layer, in contrast to outer surface-dominant uptake with 
4DST IN BASIC RESEARCH
In cancer, differential diagnosis of benign vs malignant lesions is important. Toyohara et al [26] investigated whether 4DST is useful for differentially diagnosing tumors and inflammation in animal models [26] . C6 glioma cells were transplanted into the right shoulder of Wistar rats, and turpentine was injected into the left hind leg 9 d later to create a tumor and acute inflammation C-4DST showed an extremely high tumor inflammation ratio of 49, which was comparable to that of 18 F-FE-SA5845, and was more than 10-fold higher than that of 18 F-FDG.
11
C-4DST showed a persistent increase in accumulation in the tumor and bone marrow. On the other hand, it was not retained in inflammatory tissues, and returned to the same level as in muscles 40 min after injection. As indicated here, 11 C-4DST is a useful PET tracer with high sensitivity and specificity, with completely different dynamics in tumors and inflammatory tissue. The above results strongly suggest that 11 C-4DST will be effective in clinical settings. In a follow-up study, Toyohara et al [27] evaluated longitudinal changes in 11 C-4DST uptake in turpentineinduced acute, subacute, and chronic phases of inflammatory tissues [27] . They found that 11 C-4DST uptake in inflammatory tissue was transiently increased during the subacute phase and subsequently decreased to normal levels. The transient increase in 11 C-4DST A B C Figure 9 4'-[methyl-11 C]-thiothymidine images in multiple myeloma. 18 F-FDG (A), 11 C-MET (B), and 11 C-4DST (C) PET images obtained in a 63-year-old man with multiple myeloma. Numerous active lesions are visible in the three maximum intensity projection images. The fusion images are for the cross-section at the level indicated by the red lines (D). The lesion in the right ischium (red arrow) was positive in all three PET scans. However, the lesion in the right pubis (white arrow) was only positive on the 11 C-MET and 11 C-4DST PET scans and was equivocal on the 18 F-FDG PET scan. Reprinted from Okasaki et al [24] , with the permission of Springer. , and coronal 18 F-FDG PET (E) images are shown. The uptake of 11 C-4DST was predominantly near the outer surface of the RCC tumor; the uptake of 18 F-FDG was more diffuse. Reprinted from Minamimoto et al [25] , with the permission of Springer. 
